Topical Triumph: A Case Report of Severe Generalized Plaque Psoriasis with Rapid Resolution on Tapinarof
Main Article Content
Keywords
Tapinarof, plaque psoriasis, topical therapy, severe psoriasis, case report
Abstract
Introduction: Plaque psoriasis is a chronic, immune-mediated disease characterized by erythematous, scaly plaques that can often have a significant impact on quality of life. Severe cases often require systemic or biologic therapy, though newer topical agents, like tapinarof, are increasing the number of options.
Case Report: A 54-year-old female with a long history of generalized plaque psoriasis presented with severe disease, including lesions on the scalp, trunk, groin, and extremities. Her Psoriasis Physician Global Assessment (PGA) score was severe with a pruritus intensity of 10/10. Initial therapy consisted of clobetasol cream twice daily for two weeks, followed by daily application of tapinarof 1% cream. Additional prescriptions included calcipotriene and symptomatic therapies for pruritus, while biologic initiation was considered pending laboratory evaluation. At four-month follow-up, the patient reported consistent daily use of tapinarof with complete clearance of psoriatic lesions and resolution of pruritus (0/10). She expressed high satisfaction with the therapeutic outcome, and biologic therapy was deferred.
Conclusion: This case highlights the potential of tapinarof monotherapy in achieving rapid and complete clearance of severe generalized plaque psoriasis, potentially avoiding the need for systemic or biologic escalation.
References
2. Armstrong AW, McConaha JL. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: a novel topical therapy targeting the aryl hydrocarbon receptor. J Manag Care Spec Pharm. 2023;29(12-a Suppl):S1-S13. doi:10.18553/jmcp.2023.29.12-a.s1
3. Bobonich M, Gorelick J, Aldredge L, et al. Tapinarof, a novel, first-in-class, topical therapeutic aryl hydrocarbon receptor agonist for the management of psoriasis. J Drugs Dermatol. 2023;22(8):779-784. doi:10.36849/jdd.7317
4. Nogueira S, Rodrigues MA, Vender R, Torres T. Tapinarof for the treatment of psoriasis. Dermatol Ther. 2022;35(12):e15931. doi:10.1111/dth.15931
5. Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059-1067. doi:10.1016/j.jaad.2020.10.085
6. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. doi:10.1056/NEJMoa2103629
7. Stein Gold L, Bhatia N, Tallman AM, Rubenstein DS. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes. J Am Acad Dermatol. 2021;84(3):624-631. doi:10.1016/j.jaad.2020.04.181
8. Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714-721. doi:10.1016/j.jaad.2018.10.037
9. Grossmann MC, Pixley JN, Feldman SR. A review of topical tapinarof for the treatment of plaque psoriasis. Ann Pharmacother. 2023;57(5):503-512. doi:10.1177/10600280231164775
10. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800-806. doi:10.1016/j.jaad.2022.06.1171
11. Bissonnette R, Saint-Cyr Proulx E, Jack C, Maari C. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research. J Eur Acad Dermatol Venereol. 2023;37(6):1168-1174. doi:10.1111/jdv.18925
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.